The Protective Potential of Butyrate against Colon Cancer Cell Migration and Invasion Is Critically Dependent on Cell...

Area of Science:

• Colorectal cancer research
• Molecular oncology
• Gut microbiome metabolites

Background:

• Short-chain fatty acids, like butyrate, are produced by gut bacteria fermenting dietary fiber.
• Preclinical studies suggest butyrate has anticancer properties, but clinical results vary.
• The differential effectiveness of butyrate in cancer treatment may be linked to specific cancer cell types.

Purpose of the Study:

• To investigate the impact of butyrate on colorectal cancer (CRC) cell migration and invasion.
• To determine if butyrate's efficacy varies across different human CRC cell lines (HCT116, HT-29, Caco-2).
• To explore the relationship between butyrate treatment, key signaling proteins (FAK, Src, E-cadherin), and patient survival.

Main Methods:

• Treatment of three distinct human colorectal cancer (CRC) cell lines (HCT116, HT-29, Caco-2) with varying concentrations of butyrate (0-4 mM).
• Assessment of cancer cell migration and invasion inhibition.
• Quantification of focal adhesion kinase (FAK), sarcoma (Src), and E-cadherin protein levels.
• Analysis of public cancer database for E-cadherin expression and patient survival rates.

Main Results:

• Butyrate demonstrated a dose-dependent inhibition of migration and invasion in all tested CRC cell lines.
• The inhibitory effect on FAK and Src proteins was more pronounced in HCT116 and HT-29 cells compared to Caco-2 cells.
• E-cadherin protein expression was significantly higher in HCT116 cells than in HT-29 and Caco-2 cells.
• CRC patients with higher E-cadherin expression exhibited a 13% improved 5-year survival rate.

Conclusions:

• Butyrate's anti-cancer effects on colorectal cancer cells are cell-type dependent.
• The efficacy of butyrate is associated with modulation of the FAK/Src/E-cadherin signaling pathway.
• E-cadherin expression is a potential prognostic marker for colorectal cancer survival.